Alnylam submits cta application for aln-xdh, an investigational rnai therapeutic for the treatment of gout

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the company has submitted a clinical trial authorization (cta) application to the medicines and healthcare products regulatory agency (mhra) in the united kingdom to initiate a phase 1/2 study of aln-xdh, an investigational rnai therapeutic targeting xanthine dehydrogenase (xdh) for the treatment of gout. upon obtaining mhra approval, the company plans to
ALNY Ratings Summary
ALNY Quant Ranking